Donald Küfe

Boston University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

122h-index50.3kcitations1.2kworks0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glycosylation and Glycoproteins Research(249), Immunotherapy and Immune Responses(149), Monoclonal and Polyclonal Antibodies Research(110), RNA modifications and cancer(107), Cancer, Hypoxia, and Metabolism(74)

Publications1.2k total

Supplemental Table S1 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Figure S8 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Figure S6 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Figure S2 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Figure S5 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Figure S4 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
Figure S7 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
2025Open Access
M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors
2025Open Access
Supplementary Figures S1-S9 and Tables S1-S4. from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
2025Open Access
Figure 3 from Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non–neuroendocrine Small Cell Lung Cancer
2025Open Access
Figure 5 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
2025Open Access
MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer
Signal Transduction and Targeted Therapy·2025· 2 citedOpen Access
Figure 1 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
2025Open Access
Figure 6 from Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non–neuroendocrine Small Cell Lung Cancer
2025Open Access
Figure 2 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
2025Open Access
Figure 5 from Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non–neuroendocrine Small Cell Lung Cancer
2025Open Access
Figure 4 from Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non–neuroendocrine Small Cell Lung Cancer
2025Open Access
Figure 3 from MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer
2025Open Access
Figure 2 from Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non–neuroendocrine Small Cell Lung Cancer
2025Open Access
Figure 1 from Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non–neuroendocrine Small Cell Lung Cancer
2025Open Access
page 1 of 58Next →

Frequent Co-authors

Surender Kharbanda(14), Ralph R. Weichselbaum(9), Pramod S. Pandey(7), Dongshu Chen(6), Ajit Bharti(5), Dennis E. Hallahan(4), Kiyotsugu Yoshida(4), Yongqing Li(4), David Avigan(4), Jianlin Gong(4), Michael A. Beckett(3), Helena J. Mauceri(3), Vikas P. Sukhatme(3), Miyako Abe(3), Daniel F. Hayes(3), Rakesh Datta(3), Yinyin Huang(3), Satya Saxena(3), Zhi-Min Yuan(3), Carlo M. Nalin(3)